Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes

[1]  V. Tesar,et al.  Soluble receptor for advanced glycation end products in patients with decreased renal function. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  H. Kaneto,et al.  Endogenous secretory receptor for advanced glycation end product levels are inversely associated with HbA1c in type 2 diabetic patients. , 2006, Diabetes care.

[3]  S. Fukumoto,et al.  Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[4]  H. Kaneto,et al.  Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. , 2005, Diabetes care.

[5]  A. D'Angelo,et al.  Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension , 2005, Journal of hypertension.

[6]  S. Jacqueminet,et al.  Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. , 2005, Clinical chemistry.

[7]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[8]  Merlin C. Thomas,et al.  Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[9]  A. D'Angelo,et al.  Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[10]  A. Schmidt,et al.  Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[11]  J. Enghild,et al.  Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)* , 2004, Journal of Biological Chemistry.

[12]  Jeon-Soo Shin,et al.  Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. , 2004, Molecular immunology.

[13]  P. Rogalla,et al.  Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? , 2003, Biochimica et biophysica acta.

[14]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[15]  S. Takasawa,et al.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.

[16]  A. Schmidt,et al.  RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease , 2002, Cellular and Molecular Life Sciences CMLS.

[17]  R. Bucala,et al.  Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.

[18]  R. Bucala,et al.  Endothelial dysfunction and advanced glycation end products in type 2 diabetes mellitus , 2002 .

[19]  T. Kislinger,et al.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.

[20]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[21]  A. Barden,et al.  Advanced Glycation End Products: A Review , 2013 .

[22]  Hiroshi Yamamoto,et al.  The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[23]  K. Kawasaki,et al.  Roles of the AGE‐RAGE System in Vascular Injury in Diabetes a , 2000, Annals of the New York Academy of Sciences.

[24]  H. Yamamoto,et al.  The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. , 2000, The Journal of biological chemistry.

[25]  R. Bucala,et al.  Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts. , 2000, Bioconjugate chemistry.

[26]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[27]  J. Clausen,et al.  The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. , 1998, Diabetes care.

[28]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[29]  Alan W. Stitt,et al.  Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs , 1997, Molecular medicine.

[30]  M. Cooper,et al.  Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury , 1997, Diabetologia.

[31]  K. Gerbitz,et al.  Possible Significance of Advanced Glycation End Products in Serum in End-Stage Renal Disease and in Late Complications of Diabetes , 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[32]  P. Guillausseau,et al.  Rapid Publication , 1971, Nature.

[33]  G. Otto,et al.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.

[34]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[35]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .